Latest Synthetic Biologics Inc. Stories
ROCKVILLE, Md., Jan.
-- On Schedule to Release Topline Data from Phase 1b Clinical Trial and to Start Phase 2 Clinical Trial of SYN-004 in 1Q 2015 -- ROCKVILLE, Md., Dec.
-- First-in-Class Drug Candidate to Prevent C. difficile Ahead of Schedule for Phase 2 Testing to Begin in 1st Quarter 2015 -- ROCKVILLE, Md., Dec.
-- First-in-Class Clinical Program Targets Protection of Microbiome to Prevent Overgrowth of Deadly C. difficile Infection Linked with Use of IV Antibiotics -- ROCKVILLE, Md., Dec.
-- Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria -- ROCKVILLE, Md., Nov.
-- Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman -- ROCKVILLE, Md., Oct.
ROCKVILLE, Md., Oct.
-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept.
-- Company Expects to File IND to Support Clinical Trials in Mid-2015 -- ROCKVILLE, Md., Sept.
-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT -- ROCKVILLE, Md., Sept.
- A poem in which the author retracts something said in an earlier poem.